证券代码：688075 证券简称：安旭生物 公告编号：2025-015 杭州安旭生物科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.8元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/17 | 2025/7/18 | 2025/7/18 | 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 22 日的2024年年度股东大会审议通过。 二、分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本127,082,805股为基数，每股派发现 金红利0.8元（含税），共计派发现金红利101,666,244.00元。 三、相关日期 | 股权登记日 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Anxu Biotech, indicating a decline in revenue and profit while comparing its valuation metrics to industry averages [1][2] - Anxu Biotech's closing stock price is 39.22 yuan, with a rolling PE ratio of 31.92, marking a new low in 22 days, and a total market capitalization of 4.984 billion yuan [1] - The company ranks 70th in the medical device industry, which has an average PE ratio of 51.58 and a median of 37.46 [1][2] Group 2 - As of the first quarter of 2025, six institutions hold shares in Anxu Biotech, with a total of 50.3836 million shares valued at 1.998 billion yuan [1] - Anxu Biotech specializes in the research, production, and sales of POCT reagents and instruments, having received multiple certifications including EU CE, Canadian, and Australian certifications [1] - The latest financial report for the first quarter of 2025 shows a revenue of 115 million yuan, a year-on-year decrease of 10.90%, and a net profit of 34.0296 million yuan, down 51.52% year-on-year, with a gross margin of 42.32% [1]

Fundraising Overview - The company, Hangzhou Anxu Biotechnology Co., Ltd., successfully raised a total of RMB 1,200.30 million by issuing 15,333,400 shares at a price of RMB 78.28 per share, with a net amount of RMB 1,055.85 million after deducting various fees [1] - The funds have been deposited into a special account approved by the board of directors, and a tripartite supervision agreement has been signed with the sponsor and the bank [1] Fund Management - The company has established a fundraising management system in accordance with regulatory requirements to ensure effective use and management of the raised funds [2] - Strict approval processes are in place for the use of funds, ensuring that they are used for designated projects [2] Supervision Agreements - Multiple tripartite and quadripartite supervision agreements have been signed with various banks to regulate the management of the raised funds, with all agreements functioning normally as of December 31, 2024 [3][4][5] Account Closure - Due to the completion of certain fundraising projects, the company has decided to close specific fundraising accounts to streamline management and reduce costs [5] - The closure of these accounts has been completed, and the corresponding supervision agreements have been terminated [5]

证券代码：688075 证券简称：安旭生物 公告编号：2025-014 杭州安旭生物科技股份有限公司 关于部分募集资金账户注销的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州安旭生物科技股份有限公司（以下简称"安旭生物"或"公司"）董事会首次 公开发行股票募集资金按照相关法律、法规和规范性文件的规定在银行开立了募集资 金专项账户。近日，公司办理完成部分募集资金专用账户的注销手续，现将具体情况 公告如下： 一、 募集资金基本情况 根据中国证券监督管理委员会于 2021 年 9 月 28 日出具的《关于同意杭州安旭生 物科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕3138 号），公 司获准向社会公开发行人民币普通股 15,333,400 股，每股发行价格为人民币 78.28 元， 募集资金总额为 120,029.86 万元；扣除承销及保荐费用、发行登记费以及其他交易费 用共计 14,445.23 万元（不含增值税金额）后，募集资金净额为 105,584.63 万元，上述 资金已全部到位，经信永 ...

Company Overview - Anxu Bio focuses on the research, development, production, and sales of POCT reagents and instruments [1] - The company has been recognized as a "Zhejiang Province Intellectual Property Demonstration Enterprise" and a "National Intellectual Property Advantage Enterprise" [1] - As of 2024, Anxu Bio has obtained a total of 305 authorized patents, including 43 invention patents [1] Financial Performance - For Q1 2025, Anxu Bio reported a revenue of 115 million yuan, a year-on-year decrease of 10.90% [1] - The net profit for the same period was approximately 34.03 million yuan, reflecting a year-on-year decline of 51.52% [1] - The gross profit margin for the company stood at 42.32% [1] Market Position - Anxu Bio's current price-to-earnings (PE) ratio is 30.77, compared to the industry average of 49.12 and the industry median of 36.07 [2] - The company's total market capitalization is 4.805 billion yuan [1][2] - As of Q1 2025, six institutions hold shares in Anxu Bio, with a total holding of approximately 50.38 million shares valued at 1.998 billion yuan [1]

Company Overview - Anxu Bio focuses on the research, production, and sales of POCT reagents and instruments, and has been recognized as a "Zhejiang Province Intellectual Property Demonstration Enterprise" and a "National Intellectual Property Advantage Enterprise" [1] - As of March 31, 2025, Anxu Bio had 5,935 shareholders, a decrease of 278 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Financial Performance - For Q1 2025, Anxu Bio reported revenue of 115 million yuan, a year-on-year decrease of 10.90%, and a net profit of 34.03 million yuan, down 51.52% year-on-year, with a gross profit margin of 42.32% [1] Market Position - Anxu Bio's current rolling price-to-earnings (PE) ratio is 30.51, while the average PE ratio for the medical device industry is 49.10, and the industry median is 36.43, placing Anxu Bio at the 69th position in the industry ranking [1][2] - The company's total market capitalization is 4.763 billion yuan [1][2] Intellectual Property and Certifications - In 2024, Anxu Bio added 44 new authorized patents, including 13 invention patents, bringing the total to 305 authorized patents, of which 43 are invention patents [1] - The company has obtained multiple authoritative certifications, including EU CE certification, Canadian certification, and Australian certification, with a total of 1,580 certifications, including 606 new certifications in the latest period [1]

Core Viewpoint - The report indicates that Hangzhou Anxu Biotechnology Co., Ltd. has maintained a sound governance structure and effective internal controls during the continuous supervision period, with no violations in fundraising, related transactions, or operational status [1][5]. Group 1: Company Governance and Internal Control - The company’s articles of association and governance systems are complete and effectively executed [2]. - The board of directors, supervisors, and senior management fulfill their responsibilities as required [2]. - Internal control systems are effectively implemented [2]. Group 2: Information Disclosure - The company has fulfilled its information disclosure obligations accurately and completely, with no false records or misleading statements [2][5]. Group 3: Independence and Related Party Transactions - The company maintains independence in assets, personnel, finance, and business, with no violations regarding the occupation of company funds by related parties [3][4]. Group 4: Fundraising and Usage - The company has adhered to fundraising management regulations, with funds stored in dedicated accounts and no unauthorized changes in usage [3][4]. Group 5: Related Transactions and Investments - There are no violations regarding external guarantees, related transactions, or significant external investments during the supervision period [4][5]. Group 6: Operational Status - The company’s business model and structure have not undergone significant adverse changes, and its operational status remains normal [4][5]. Group 7: Compliance and Recommendations - The company is advised to continue improving its governance structure and ensure timely information disclosure while managing fundraising effectively [5].

民生证券股份有限公司 关于杭州安旭生物科技股份有限公司 2024 年度持续督导工作现场检查报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法律、 法规的规定，民生证券股份有限公司（以下简称"保荐机构"）作为杭州安旭 生物科技股份有限公司（以下简称"安旭生物"或"公司"）首次公开发行股 票并在科创板上市的保荐机构，对公司 2024 年度（以下简称"本持续督导 期"）的规范运作情况进行了现场检查，现就有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐机构 民生证券股份有限公司 （二）保荐代表人 孙闽、朱仙掌 （三）现场检查时间 2025 年 5 月 19 日 （四）现场检查人员 朱仙掌 （五）现场检查内容 公司治理、内部控制，信息披露，独立性以及与控股股东、实际控制人及 其他关联方资金往来情况，募集资金使用，关联交易、对外担保、重大对外投 资，经营状况等。 （六）现场检查手段 1、查看公司主要生产经营场所，对公司相关人员进行访谈； 1 2、查阅本持续督导期间公司召开的历次三会文件； 3、查阅本持续督导期间公司的信 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-013 杭州安旭生物科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 22 日 （二） 股东大会召开的地点：浙江省杭州市莫干山路 1418-50 号 4 幢 5 楼大会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 44 | | --- | --- | | 普通股股东人数 | 44 | | 2、出席会议的股东所持有的表决权数量 | 99,699,361 | | 普通股股东所持有表决权数量 | 99,699,361 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 78.4522 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 78.4522 ...

上海市锦天城律师事务所 关于杭州安旭生物科技股份有限公司 2024 年年度股东大会的 法律意见书 锦 天 城 律师事务 所 ALLBRIGHT LAW OFFICES 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 传真: 021-20511999 电话: 021-20511000 邮编: 200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 一、 本次股东大会召集人资格及召集、召开的程序 经核查,公司本次股东大会由公司董事会召集召开。公司已于 2025年 4 月 30 日在上海证券交易所网站(http://www.sse.com.cn)和《上海证券报》和《证 券日报》上刊登《杭州安旭生物科技股份有限公司关于召开 2024年年度股东大 会的通知》,将本次股东大会的召开时间、地点、审议事项、出席会议人员、登 1 上海市锦天城律师事务所 关于杭州安旭生物科技股份有限公司 2024 年年度股东大会的 法律意见书 致:杭州安旭生物科技股份有限公司 上海市锦天城律师事务所(以下简称"本所")接受杭州安旭生物科技股份 有限公司(以下简称"公司")委托,就公司召开 2024年年 ...